An observational study in Constipation, sponsored by Jinling Hospital, China. Status unknown at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-04.
Sponsored by Jinling Hospital, China · Observational
Constipation is a heterogeneous and multifactorial disease, influenced by a number of different genetic and environmental factors. By applying the standard two-stage GWAS strategy to design and carry out a metagenome-wide association study (MGWAS) to find the relationship between gut microbiota and constipation, to identify disease-associated metagenomic markers.
This study is a two-stage case-control metagenome-wide association study (MGWAS) based on deep next-generation shotgun sequencing of DNA extracted from the stool samples from a total of 50 Chinese constipation patients and healthy controls.
1,018 studies on the registry are indexed under Constipation; 139 are open to participants now.
This study's planned enrollment of 50 is below the median of 100 across 129 observational studies indexed under Constipation.
Browse Constipation studies →Jinling Hospital, China is the lead sponsor of 126 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
50 faecal samples were obtained from constipation patients and 50 faecal samples were obtained from healthy volunteers
Exclusion Criteria:
collect stool samples from constipation patients
collect stool samples from healthy controls patients
taxonomic and functional characterization of gut microbiota
Time frame: one year
Gut-microbiota-based constipation classification
Time frame: one year
constipation-associated gut microbial markers
Time frame: one year
This study is status unknown, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jinling Hospital, China